
|Videos|February 24, 2019
Dr. Lulla Discusses Post-Transplant Options for Leukemias
Author(s)Premal Lulla, MD
Premal Lulla, MD, discusses the need for cellular therapies for patients with leukemia after transplant.
Advertisement
Premal Lulla, MD, assistant professor of medicine at the Center for Cell and Gene Therapy, Texas Children's Hospital, discusses the need for cellular therapies for patients with leukemia after transplant.
Patients who relapse posttransplant have a very poor prognosis, says Lulla. In this setting, there are no approved treatment options in the frontline setting.
Lulla believes the posttransplant environment has room for immunotherapy to improve outcomes.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5




































